Sperling sat down with NeurologyLive at AAIC 2019 to discuss her thoughts on efforts to detect and treat Alzheimer early on in the disease.
“Recent trial results are thought-provoking and soul searching, but we have to learn from them.”
At the 2019 Alzheimer’s Association International Conference, Reisa Sterling, MD, Director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital and Massachusetts General Hospital, and professor of Neurology at Harvard Medical School, sat down with NeurologyLive to discuss advances in the detection and treatment of Alzheimer disease.
Sterling suggests that tau therapies are promising. More importantly, she stresses early detection, with a focus on patients who are not yet amyloid positive. Sterling believes that positron emission tomography (PET) scans, while costly, should be used to detect Alzheimer at an early stage, especially in clinical trials.
In this interview, Sterling shared her expert insight on the disease that affects more than 5 million Americans.